Perhaps the two hottest themes in the markets right are the move in the US Dollar and what is going on in the Biotech sector. I have hit on the USD a few times, but let me take a shot at Biotech. More specifically, I want to highlight the …
It's been a less-than-stellar year for biotech blue chip Gilead Sciences (NASDAQ: GILD). The company's stock has been mired in a pretty steady downtrend since June 2015, and, over the trailing 12 months, it's off an unsightly 26%. Mind …
Gilead Sciences, Inc. (NASDAQ:GILD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday. The brokerage presently has a $76.00 price objective on the biopharmaceutical …
This pattern could be signalling the beginning of a bear market for GILD stock. A surge in share price would negate this pattern, but until such an event presents itself, the pattern is bearish and worrisome. READ Hanjin bankruptcy causes …
10 stocks we like better than Gilead Sciences When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they …
Gilead Sciences
Gilead Sciences (ticker: GILD) repurchased $565 million of shares in the first quarter, even less than the $1 billion of buybacks in the fourth quarter, indicating …
Gilead Cut Buybacks
Gilead Sciences, Inc., GILD from Healthcare exhibited a market capitalization of 87.06B. Companies having a market cap of $10 billion or more are typically considered as the major players of the market. With today’s market cap for Gilead
Gilead Sciences Inc. (NASDAQ:GILD) stock is down 24% over the course of a year. But even though the past year has not been great, GILD stock’s valuation still makes it attractive. The price-to-earnings (P/E) ratio for.
Kyle Anderson: Gilead Sciences Inc. (NASDAQ:GILD) is facing criticism again this week for its highly priced Hepatitis C drug Sovaldi. The drug costs $1,000 per pill. According to The Wall Street Journal, many states have restricted access …
Gilead Sciences Inc (NASDAQ: GILD) missed consensus estimates for revenues and EPS for Q1FY18. The company reported revenues of $6.51 billion and EPS of $2.23. Sales fell by 16.5% YoY. The bottom line was at $2.95 billion Vs …
NASDAQ